Aldeyra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Aldeyra Therapeutics

08/03/2024 04:30

* Aldeyra Therapeutics Inc  ALDX.OQ  reported a quarterly
adjusted
loss of 8 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -22 cents.  The mean expectation of
eight analysts for the quarter was for a loss of 14 cents per
share. Wall Street expected results to range from -24 cents to 1
cents per share.
    * Reported revenue was zero​; analysts expected $1.86
million. 
    * Aldeyra Therapeutics Inc's reported EPS for the quarter
was a
loss of 8 cents​.
    * The company reported a quarterly loss of $4.75 million.
    * Aldeyra Therapeutics Inc shares had risen by 12.0% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 18.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Aldeyra
Therapeutics Inc is $9.00 
This summary was machine generated from LSEG data March 8 at
04:30 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.14          -0.08          Beat
 Sep. 30 2023      -0.24          -0.14          Beat
 Jun. 30 2023      -0.31          -0.15          Beat
 Mar. 31 2023      -0.29          -0.27          Beat